Stock listing
NASDAQ:ETRA Electra Therapeutics, Inc. Stock
Home listing (NASDAQ) of Electra Therapeutics, Inc.
Follow Electra Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ETRA
$8.11 USD -0.32 (-3.8%)
Close on Nov 20, 2026
- Day range
- $8.07 – $9.65 USDNov 20, 2026
- Volume
- 376,123 sharesNov 20, 2026
- Market cap
- $509.8M USDAt the close on Nov 20, 2026 · price × 62.87M shares outstanding
- Traded on an average day
- $5.74M USDMedian day 398,089 shares · 1 day with no trades · last 3 months, Sep 17, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ETRA · Home | $8.11 USD | -0.32 (-3.8%) | 376,123 | $8.85 | $9.65 | $8.07 | $8.43 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Sep 17, 2026 – Nov 20, 2026 · NASDAQ:ETRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.11 | -0.32 | -3.8% | $8.85 | $9.65 | $8.07 | 376,123 | |
| $8.43 | +0.08 | +1.0% | $8.40 | $8.97 | $8.40 | 323,440 | |
| $8.35 | +0.04 | +0.5% | $8.43 | $8.97 | $8.09 | 332,194 | |
| $8.31 | -0.53 | -6.0% | $8.82 | $9.265 | $8.015 | 394,876 | |
| $8.84 | -0.27 | -3.0% | $9.37 | $9.37 | $7.62 | 313,149 | |
| $9.11 | -0.34 | -3.6% | $9.53 | $9.882 | $8.67 | 545,248 | |
| $9.45 | +1.46 | +18.3% | $8.25 | $9.485 | $8.18 | 385,193 | |
| $7.99 | -0.23 | -2.8% | $8.02 | $8.86 | $7.835 | 298,184 | |
| $8.22 | +0.42 | +5.4% | $7.70 | $8.69 | $7.401 | 428,272 | |
| $7.80 | +0.45 | +6.1% | $7.72 | $8.095 | $7.20 | 401,301 | |
| $7.35 | -0.62 | -7.8% | $7.95 | $7.99 | $6.97 | 524,741 | |
| $7.97 | -0.10 | -1.2% | $8.07 | $8.25 | $6.88 | 437,028 | |
| $8.07 | +0.76 | +10.4% | $7.30 | $8.15 | $7.025 | 927,338 | |
| $7.31 | -0.79 | -9.8% | $8.00 | $8.375 | $7.055 | 385,464 | |
| $8.10 | -0.54 | -6.3% | $8.385 | $8.48 | $7.945 | 150,482 | |
| $8.64 | -0.34 | -3.8% | $8.94 | $9.17 | $8.55 | 166,475 | |
| $8.98 | +0.46 | +5.4% | $8.36 | $9.21 | $8.36 | 177,304 | |
| $8.52 | +0.15 | +1.8% | $8.37 | $8.88 | $8.32 | 176,272 | |
| $8.37 | -0.34 | -3.9% | $8.98 | $9.175 | $8.26 | 159,047 | |
| $8.71 | -0.54 | -5.8% | $9.30 | $9.35 | $8.71 | 186,453 | |
| $9.25 | +0.20 | +2.2% | $9.18 | $9.48 | $9.00 | 155,801 | |
| $9.05 | +0.24 | +2.7% | $8.89 | $9.273 | $8.81 | 126,068 | |
| $8.81 | +0.20 | +2.3% | $8.75 | $9.17 | $8.71 | 177,913 | |
| $8.61 | -0.14 | -1.6% | $8.72 | $8.885 | $8.56 | 308,987 | |
| $8.75 | 0.00 | 0.0% | $8.74 | $9.16 | $8.50 | 1,380,500 | |
| $8.75 | -0.19 | -2.1% | $8.97 | $8.99 | $8.58 | 179,600 | |
| $8.94 | +0.33 | +3.8% | $8.69 | $9.47 | $8.50 | 521,000 | |
| $8.61 | -0.71 | -7.6% | $9.39 | $9.80 | $8.57 | 552,300 | |
| $9.32 | +0.28 | +3.1% | $8.99 | $9.60 | $8.78 | 346,700 | |
| $9.04 | -0.10 | -1.1% | $9.13 | $9.30 | $8.68 | 778,500 | |
| $9.14 | -0.02 | -0.2% | $9.10 | $10.12 | $8.63 | 408,000 | |
| $9.16 | -0.66 | -6.7% | $9.72 | $9.73 | $8.92 | 407,300 | |
| $9.82 | +0.08 | +0.8% | $9.68 | $9.95 | $9.35 | 276,200 | |
| $9.74 | -0.63 | -6.1% | $10.46 | $10.46 | $9.28 | 334,400 | |
| $10.37 | -0.31 | -2.9% | $10.75 | $11.13 | $9.88 | 696,600 | |
| $10.68 | -0.57 | -5.1% | $11.14 | $11.58 | $10.46 | 1,255,400 | |
| $11.25 | -0.10 | -0.9% | $11.37 | $12.09 | $11.23 | 925,700 | |
| $11.35 | +0.03 | +0.3% | $11.21 | $11.94 | $11.00 | 715,600 | |
| $11.32 | -0.23 | -2.0% | $11.52 | $11.91 | $11.14 | 537,100 | |
| $11.55 | -0.27 | -2.3% | $11.70 | $12.75 | $11.27 | 438,400 | |
| $11.82 | -0.85 | -6.7% | $12.54 | $13.56 | $11.71 | 445,200 | |
| $12.67 | -0.95 | -7.0% | $13.56 | $14.18 | $12.50 | 875,400 | |
| $13.62 | -0.30 | -2.2% | $13.88 | $14.12 | $13.11 | 439,700 | |
| $13.92 | +0.67 | +5.1% | $13.94 | $14.48 | $13.48 | 813,200 | |
| $13.25 | -1.75 | -11.7% | $15.00 | $15.50 | $13.25 | 5,124,319 | |
| $15.00 | — | — | $15.00 | $15.00 | $15.00 | 0 |
- Ticker
- NASDAQ:ETRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
Latest news
Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
Nov 12, 2026
Closed $8.84 (-3.0%) on Nov 13, 2026
Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
Nov 4, 2026
Closed $7.97 (-1.2%) on Nov 4, 2026
Oura Targets $15.6 Billion Valuation in Test of IPO Market — Barrons.com
Sep 21, 2026
Closed $13.92 (+5.1%) on Sep 21, 2026
Antibody therapy developer Electra upsizes IPO seeking nearly $350M
Sep 18, 2026
Closed $13.25 (-11.7%) on Sep 18, 2026
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
Sep 17, 2026
Closed $13.25 (-11.7%) on Sep 18, 2026
Electra Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 5 in all · newest Nov 12, 2026 · oldest 2026
Where Electra Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ETRA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ETRA | BOATS | United States | USD |
Valuation
Price/book 1.3× against a median of 2.2×: 2nd lowest of 10 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $107.3M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.7M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$497.0M | US$470.5M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.3M | n/a | 23.3× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.8M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Median of the others | US$503.5M | US$316.2M | 19.7× | 2.2× | −503.7% | 0.0× | 1.61 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.27 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Kathy Dong | President, Chief Executive Officer and Director |
| Chris Clark | Chief Financial Officer |
| Gary S. Koe | Chief Technical Officer |
| Graham Parry | Chief Scientific Officer |
| Kim-Hien Dao | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Nancy Stagliano | Chairperson |
| Adam Rosenthal | Director |
| Beth Seidenberg | Director |
| Carl L. Gordon | Director |
| Kathy Dong | President, Chief Executive Officer and Director |
| Matthew Fust | Director |
| Thomas Geninatti | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −3.0% |
Financings
| Raise | Date |
|---|---|
| Public offering of shares Made bigger: US$350M · US$15 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Cantor (co-lead) Use of proceeds: To advance lead asset ipsoprubart and for other business activities, including working capital | Sep 18, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Sep 17, 2026.
- Price
- US$15.00 a share
- Shares offered
- 23,333,334 shares of common stock
- Offering size
- US$350 million
- Underwriters' option
- Up to 3,500,000 more shares
- Listing
- ETRA on the Nasdaq Global Select Market
- Underwriters
- Jefferies, TD Cowen, Evercore ISI, Cantor · In the order on the cover
- Shares delivered
- On or about Sep 21, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 26, 2026 |
| Filed publicly | Aug 28, 2026 |
| Amended once | Sep 14, 2026 |
| Declared effective by the SEC | Sep 17, 2026 |
| Shares registered with an exchange | Sep 18, 2026 |
| Final prospectus, with the price | Sep 18, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 18, 2026 |
| CERT · Exchange's certificate of listing | Sep 18, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 18, 2026 |
| EFFECT · Notice that a registration is effective | Sep 17, 2026 |
| S-1MEF · Registration of more shares for the same offering | Sep 17, 2026 |
| S-1/A · Registration statement, amended | Sep 14, 2026 |
| S-1 · Registration statement | Aug 28, 2026 |
| DRS/A · Draft registration statement, amended | Aug 10, 2026 |
| DRS · Draft registration statement | Jun 26, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 50.4M | 19.3M |
| Selling, general and administrative | 11.5M | 7.05M |
| Operating income | -61.9M | -26.3M |
| Depreciation and amortization | 61.0K | 0 |
| EBITDA | -61.8M | -26.3M |
| Interest expense | 1.40M | 0 |
| Income before tax | -62.0M | -24.8M |
| Net income | -62.0M | -24.8M |
| Earnings per share, basic | -2,113.10 | -0.39 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 33.0M | 14.8M |
| Short-term investments | 53.5M | 998.0K |
| Receivables | 220.0K | |
| Current assets | 95.5M | 19.4M |
| Property, plant and equipment | 674.0K | |
| Total assets | 99.4M | 19.4M |
| Accounts payable | 4.08M | 1.53M |
| Current liabilities | 9.73M | 4.20M |
| Total debt | 2.09M | |
| Total liabilities | 11.2M | 122.7M |
| Shareholders' equity | -163.4M | -103.3M |
| Shares outstanding | 29.3K | 62.8M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -60.5M | -26.0M |
| Capital spending | -733.0K | 0 |
| Free cash flow | -61.2M | -26.0M |
| Cash from investing | -53.0M | |
| Cash from financing | 131.7M | 0 |
| Change in cash | 18.2M | 3.70M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 28, 2026 | Big-stake notice | SEC |
All 41 filings
Cap table
Built by 6ix from Electra Therapeutics, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 62,866,792
- Fully diluted
- 62,866,792
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 62,866,792 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 62,866,792 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Matthew Fust Other companies: Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Ultragenyx Pharmaceutical Inc. (Director · Since at least Jun 24, 2022); Atara Biotherapeutics, Inc. (Director · Since at least Jun 23, 2022); Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 17, 2022) | Director · Since at least Sep 18, 2026 |
| Carl L. Gordon Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 28, 2026); BlossomHill Therapeutics, Inc. (Director · Since at least Aug 10, 2026) | Director · Since at least Sep 21, 2026 |
| Nancy Stagliano Other companies: Pandion Therapeutics Inc (Director · Jul 16, 2020 – Apr 1, 2021 · Past) | Chairperson · Since at least Sep 18, 2026 |
| Adam Rosenthal | Director · Since at least Nov 5, 2026 |
| Beth Seidenberg | Director · Since at least Nov 4, 2026 |
| Chris Clark | Chief Financial Officer · Since at least Nov 4, 2026 |
| Christopher William Clark | Chief Financial Officer · Since at least Sep 18, 2026 |
| David J Tucker | Principal Accounting Officer · Since at least Sep 18, 2026 |
| Gary S. Koe | Chief Technical Officer · Since at least Sep 18, 2026 |
| Graham Parry | Chief Scientific Officer · Since at least Sep 21, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Kathy Dong | President, Chief Executive Officer and Director · Since at least Nov 4, 2026 |
| Kim-Hien Dao | Chief Medical Officer · Since at least Nov 5, 2026 |
| Quehuong Dong | President & CEO, Director · Since at least Sep 21, 2026 |
| Thomas Geninatti | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Electra Therapeutics, Inc.